Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas. |
|
Press Release - ADVENTRX Pharmaceuticals, Inc. (ANX-NYSE Amex) |
|
|
“ADVENTRX stands out among its small cap peers because we expect to submit an NDA, the final regulatory hurdle to drug approval, this year. There is only a limited amount of work remaining before we submit that NDA, and we have both the financial and human capital to get there.” - Brian M. Culley, M.A., M.B.A. (ANX) (Interview published June 18, 2010) |
The Most Powerful Name In Corporate News and Information. |
|
CURRENT ISSUE | COVER ARCHIVES | INDEX | CONTACT | FINANCIALS | MARKETING SERVICES | HOME PAGE |
|
Webcast Alert: ADVENTRX Pharmaceuticals, Inc. Announces LHA Life Sciences & Med Tech Day 2010 Presentation
LHA Life Sciences & Med Tech Day 2010 What: Presentation When: July 20, 2010 @ 10:00 AM Eastern http://www.investorcalendar.com/ Where: ClientPage.asp?ID=160318 Live over the Internet --Simply log on to the How: web at the address above.
Contact: Cheryl Palazzo, 212-838-3777, cpalazzo@lhai.com
If you are unable to participate during the live webcast, the call will be available for replay at http://www.investorcalendar.com/ClientPage.asp?ID=160318 or http://www.investorcalendar.com/ ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) is a specialty pharmaceutical company whose product candidates are designed to improve upon existing cancer treatments by addressing limitations associated with their safety and use. Its lead product candidates include ANX-530, a novel emulsion formulation of the chemotherapy drug vinorelbine (Navelbine(R)), to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin and advanced or metastatic breast cancer; and ANX-514, a detergent-free emulsion formulation of the chemotherapy drug docetaxel (Taxotere(R)) for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers. The Company expects to file an NDA for ANX-530 in the fourth quarter of 2010. Additional information regarding ADVENTRX is available at http://www.adventrx.com/ SOURCE ADVENTRX Pharmaceuticals, Inc.
|
ceocfointerviews.com does not purchase or
make
recommendation on stocks based on the interviews published.